Endocan measurement for the postmortem diagnosis of sepsis

Legal Medicine

Volumn 16, Issue 1, 2014, Pages 1-7

  Palmiere, Cristian ^a   Augsburger, Marc ^a  

^a UNIVERSITY CENTER OF LEGAL MEDICINE   (Switzerland)

Author keywords

C reactive protein; Endocan; Forensic pathology; Postmortem biochemistry; Procalcitonin; Sepsis

Indexed keywords

C REACTIVE PROTEIN; ENDOTHELIAL CELL SPECIFIC MOLECULE 1; PROCALCITONIN; PROTEOGLYCAN; UNCLASSIFIED DRUG;

ARTERIAL BLOOD; ARTICLE; AUTOPSY; CLINICAL ARTICLE; CONTROLLED STUDY; DIAGNOSTIC TEST ACCURACY STUDY; FALSE NEGATIVE RESULT; FALSE POSITIVE RESULT; FATALITY; FEMORAL ARTERY; FORENSIC IDENTIFICATION; HUMAN; IN VIVO STUDY; MEDICOLEGAL ASPECT; PERICARDIAL EFFUSION; PROSPECTIVE STUDY; PROTEIN ANALYSIS; PROTEIN EXPRESSION; SENSITIVITY AND SPECIFICITY; SEPSIS;

C-REACTIVE PROTEIN; CRP; EC; ENDOCAN; ENDOTHELIAL CELLS; FORENSIC PATHOLOGY; PCT; POSTMORTEM BIOCHEMISTRY; PROCALCITONIN; SEPSIS; SIRS; SYSTEMIC INFLAMMATORY RESPONSE SYNDROME;

BIOLOGICAL MARKERS; C-REACTIVE PROTEIN; CALCITONIN; DIAGNOSIS; HUMANS; NEOPLASM PROTEINS; PERICARDIAL EFFUSION; PROSPECTIVE STUDIES; PROTEIN PRECURSORS; PROTEOGLYCANS; SENSITIVITY AND SPECIFICITY; SEPSIS; SEVERITY OF ILLNESS INDEX;

EID: 84891658834     PISSN: 13446223     EISSN: 18734162     Source Type: Journal    
DOI: 10.1016/j.legalmed.2013.09.007     Document Type: Article

References (29)

1. Oku R., Oda S., Nakada T.A., Nakamura M., Hirayama Y., Abe R., et al. Differential pattern of cell-surface and soluble TREM-1 between sepsis and SIRS. Cytokine 2013, 61:112-117.
2. Scherpereel A., Depontieu F., Grigoriu B., Cavestri B., Tsicopoulos A., Gentina T., et al. Endocan, a new endothelial marker in human sepsis. Crit Care Med 2006, 34:532-537.
3. Xing K., Murthy S., Liles W.C., Singh J.M. Clinical utility of biomarkers of endothelial activation in sepsis - a systematic review. Crit Care 2012, 16:R7.
4. Gaïni A., Koldkjaer O.G., Møller H.J., Pedersen C., Pedersen S.S. Comparison of high-mobility group-box 1 protein, lipopolysaccharide-binding protein and procalcitonin in severe community-acquired infections and bacteraemia: a prospective study. Crit Care 2007, 11:R76.
5. Tsokos M. Postmortem diagnosis of sepsis. Forensic Sci Int 2007, 165:155-164.
6. Tsokos M., Püschel K. Postmortem bacteriology in forensic pathology: diagnostic value and interpretation. Leg Med (Tokyo) 2001, 3:15-22.
7. Tsokos M., Reichelt U., Nierhaus A., Püschel K. Serum procalcitonin (PCT): a valuable biochemical parameter for the postmortem diagnosis of sepsis. Int J Leg Med 2001, 114:237-243.
8. Tsokos M., Reichelt U., Jung R., Nierhaus A., Püschel K. Interleukin-6 and C-reactive protein serum levels in sepsis-related fatalities during the early postmortem period. Forensic Sci Int 2001, 119:47-56.
9. Uhlin-Hansen L. C-reactive protein (CRP), a comparison of pre- and postmortem blood levels. Forensic Sci Int 2001, 124:32-35.
10. Bode-Jänisch S., Schütz S., Schmidt A., Tschernig T., Debertin A.S., Fieguth A., et al. Serum procalcitonin levels in the postmortem diagnosis of sepsis. Forensic Sci Int 2013, 226:266-272.
11. Reichelt U., Jung R., Nierhaus A., Tsokos M. Serial monitoring of interleukin-1β, soluble interleukin-2 receptor and lipopolysaccharide binding protein levels after death. A comparative evaluation of potential postmortem markers of sepsis. Int J Leg Med 2005, 119:80-87.
12. Filep J.G. Endocan or endothelial cell-specific molecule-1: a novel prognostic marker of sepsis?. Crit Care Med 2006, 34:574-575.
13. Roudnicky F., Poyet C., Wild P. Endocan is upregulated on tumor vessels in invasive bladder cancer where it mediates VEGF-A-induced angiogenesis. Cancer Res 2013, 73:1097-1106.
14. Chen L.Y., Liu X., Wang S.L., Qin C.Y. Over-expression of the endocan gene in endothelial cells from hepatocellular carcinoma is associated with angiogenesis and tumor invasion. J Int Med Res 2010, 38:498-510.
15. Abid M.R., Yi X., Yano K., Shih S.C., Aird W.C. Vascular endocan is preferentially expressed in tumor endothelium. Microvasc Res 2006, 72:136-145.
16. Grigoriu B.D., Depontieu F., Scherpereel A., Gourcerol D., Devos P., Ouatas T., et al. Endocan expression and relationship with survival in human non-small cell lung cancer. Clin Cancer Res 2006, 12:4575-4582.
17. Scherpereel A., Gentina T., Grigoriu B., Sénéchal S., Janin A., Tsicopoulos A., et al. Overexpression of endocan induces tumor formation. Cancer Res 2003, 63:6084-6089.
18. Zuo L., Zhang S.M., Hu R.L., Zhu H.Q., Zhou Q., Gui S.Y., et al. Correlation between expression and differentiation of endocan in colorectal cancer. World J Gastroenterol 2008, 14:4562-4568.
19. Huang G.W., Tao Y.M., Ding X. Endocan expression correlated with poor survival in human hepatocellular carcinoma. Dig Dis Sci 2009, 54:389-394.
20. Leroy X., Aubert S., Zini L., Franquet H., Kervoaze G., Villers A., et al. Vascular endocan (ESM-1) is markedly overexpressed in clear cell renal cell carcinoma. Histopathology 2010, 56:180-187.
21. Zhang S.M., Zuo L., Zhou Q., Gui S.Y., Shi R., Wu Q., et al. Expression and distribution of endocan in human tissues. Biotech Histochem 2012, 87:172-178.
22. Sarrazin S., Adam E., Lyon M., Depontieu F., Motte V., Landolfi C., et al. Endocan or endothelial cell specific molecule-1 (ESM-1): a potential novel endothelial cell marker and a new target for cancer therapy. Biochim Biophys Acta 2006, 1765:25-37.
23. Maurage C.A., Adam E., Minéo J.F., Sarrazin S., Debunne M., Siminski R.M., et al. Endocan expression and localization in human glioblastomas. J Neuropathol Exp Neurol 2009, 68:633-641.
24. Bechard D., Meignin V., Scherpereel A., Oudin S., Kervoaze G., Bertheau P., et al. Characterisation of the secreted form of endothelial-cell-specific molecule 1 by specific monoclonal antibodies. J Vasc Res 2000, 37:417-425.
25. Definition for sepsis and organ failure and guidelines for the use of innovative therapies in sepsis. Crit Care Med 1992, 20:864-874. American College of Chest Physicians/Society of Critical Care Medicine Consensus Conference.
26. Wu Y., Wang F., Fan X., Bao R., No L., Li J., et al. Accuracy of plasma sTREM-1 for sepsis diagnosis in systemic inflammatory patients: a systematic review and meta-analysis. Crit Care 2012, 16:R229.
27. Li L., Zhu Z., Chen J., Ouyang B., Chen M., Guan X. Diagnostic value of soluble triggering receptor expressed on myeloid cells-1 in critically ill, postoperative patients with suspected sepsis. Am J Med Sci 2013, 345:178-184.
28. Mussap M., Noto A., Fravega M., Fanos V. Soluble CD14 subtype presepsin (sCD14-ST) and lipopolysaccharide binding protein (LBP) in neonatal sepsis: new clinical and analytical perspectives for two old biomarkers. J Matern Fetal Neonatal Med 2011, 24(Suppl. 2):12-14.
29. Hatfield K.J., Lassalle P., Leiva R.A., Lindås R., Wendelboe Ø., Bruserud Ø. Serum levels of endothelium-derived endocan are increased in patients with untreated acute myeloid leukemia. Hematology 2011, 16:351-356.